The anti-CD38 antibody daratumumab, approved for use against multiple myeloma, was augmented after fusion to either the μtp C575S or μtp, demonstrating that this technology can be applied to a wider range of targets beyond CD20. Here, CD38 is linked to AL amyloidosis.